No internet connection — showing the saved version of the page.

Alto Neuroscience…

USUSD
← to the screener

Alto Neuroscience, Inc. (US:ANRO) — Biotechnology: Pharmaceutical Preparations. Number of exchanges where the company shares trade: 1. On this page — price and chart, dividends, top holders and share count history.

About the company

Website
altoneuroscience.com
Investor relations
investors.altoneuroscience.com/overview/default.aspx
Sector
Health Care · Biotechnology: Pharmaceutical Preparations
Headquarters
MOUNTAIN VIEW, United States
Management
Amit Etkin
Latest reports
quarterly 2026 · 10-Q for the period ended 2026-03-31
Employees
68
Shares outstanding
40.11 M as of 2026-11-05
DateSharesChange
05.11.202640.11 M+2.2%issuance (dilution)
07.08.202639.24 M
Share count from the company reports. A split is detected by a jump in the count by a whole number of times.
Free float
29.59 M
Market cap
886.87 M USD
Insiders
4.21%
Institutions
88.68%
Industry (SIC)
Pharmaceutical Preparations
P/E
loss
EPS
−2.32 USD
P/B
3.58
ROE
−46.6%
FCF
−79.7 M USD
Debt
13.5 M USD
net cash
Earnings and FCF — for the 12 months to 30.09.2026 (the company's latest report).
Net income
−95.2 M USD 12 mo.
For the 12 months to 30.09.2026 (4 quarters)
Revenue0 USD
− Expenses101 M USD
Net income−95.2 M USD
History by quarter
RevenueExpensesLoss
31.12.2023: Revenue 0 · Expenses 11.8 M · Operating profit −11.8 M · Net income −11.2 M31.03.2024: Revenue 0 · Expenses 14.4 M · Operating profit −14.4 M · Net income −13.4 M30.06.2024: Revenue 0 · Expenses 18.3 M · Operating profit −18.3 M · Net income −16.0 M30.09.2024: Revenue 0 · Expenses 18.9 M · Operating profit −18.9 M · Net income −16.8 M31.12.2024: Revenue 0 · Expenses 17.0 M · Operating profit −17.0 M · Net income −15.2 M31.03.2025: Revenue 0 · Expenses 15.7 M · Operating profit −15.7 M · Net income −15.2 M30.06.2025: Revenue 0 · Expenses 18.7 M · Operating profit −18.7 M · Net income −17.7 M30.09.2025: Revenue 0 · Expenses 15.0 M · Operating profit −15.0 M · Net income −14.2 M31.12.2025: Revenue 0 · Expenses 17.1 M · Operating profit −17.1 M · Net income −16.2 M31.03.2026: Revenue 0 · Expenses 27.1 M · Operating profit −27.1 M · Net income −26.2 M30.06.2026: Revenue 0 · Expenses 29.1 M · Operating profit −29.1 M · Net income −27.6 M30.09.2026: Revenue 0 · Expenses 27.2 M · Operating profit −27.2 M · Net income −25.1 M
12.202309.2026
Green above orange is profit (revenue − expenses); red below zero is a loss.
NAV
7.42 USD · P/NAV 3.58
Balance sheet date30.09.2026
Assets327 M USD
− Liabilities30.0 M USD
= NAV (equity of the company's shareholders)297 M USD
= Tangible NAV297 M USD
Shares39 975 020
NAV per share7.42 USD
Tangible NAV per share7.42 USD
Share price (ANRO)26.5200 USD
P/NAV3.58
NAV history
Balance sheet dateNAVNAV per share
30.09.2026297 M USD7.42 USD
30.06.2026219 M USD6.25 USD
31.03.2026243 M USD6.94 USD
31.12.2025151 M USD4.73 USD
30.09.2025112 M USD4.11 USD
30.06.2025123 M USD4.56 USD
31.03.2025139 M USD5.14 USD
31.12.2024151 M USD5.61 USD
Description

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.

advertisement

Exchanges and tickers

ExchangeTickerCurrencyPriceType
US USA StocksANROUSD26.52 +2.35%common stock

Price

US:ANRO · USD
Hover / tap a day — open, close, high and low prices

Top holders

HolderStakeSharesReport date
Alpha Wave Global, LP9.45%3.71 M2026-06-30
Commodore Capital Lp6.94%2.72 M2026-06-30
Blackrock Inc.5.4%2.12 M2026-06-30
Perceptive Advisors Llc4.1%1.61 M2026-06-30
Adage Capital Partners G…4.08%1.6 M2026-06-30
Vanguard Capital Managem…3.54%1.39 M2026-06-30
Spruce Street Capital LP3.45%1.35 M2026-06-30
Vivo Capital, LLC3.08%1.21 M2026-06-30
Franklin Resources, Inc.2.58%1.01 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.58%1.01 M2026-06-30
Armistice Capital, LLC2.2%864 0002026-06-30
iShares Trust-iShares Ru…2.13%836 5222026-09-30
ETKIN AMIT (Chief Execut…≈2.12%833 9492026-05-14
Franklin Strategic Serie…0.89%347 9042026-07-31
VANGUARD INDEX FUNDS-Van…0.88%346 6182026-06-30
iShares Trust-iShares Ru…0.76%298 2732026-09-30
Fidelity Salem Street Tr…0.73%287 0332026-07-31
iShares Trust-iShares Bi…0.71%279 3482026-09-30
SPDR SERIES TRUST-State…0.64%251 0902026-09-30
T. Rowe Price Health Sci…0.58%228 0572026-06-30
Fidelity Concord Street…0.37%147 0032026-08-31
SMITH NICHOLAS CONRAD (P…≈0.2%79 0602026-10-02